Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P35590
UPID:
TIE1_HUMAN
Alternative names:
-
Alternative UPACC:
P35590; B5A949; B5A950
Background:
Tyrosine-protein kinase receptor Tie-1 plays a pivotal role in vascular development and angiogenesis, acting as a transmembrane tyrosine-protein kinase. It modulates TEK/TIE2 activity, crucial for blood vessel formation and maintenance.
Therapeutic significance:
Tie-1's involvement in Lymphatic malformation 11, characterized by lower extremity edema due to lymphatic system defects, highlights its potential as a therapeutic target. Understanding Tie-1's role could lead to novel treatments for lymphedema and related vascular anomalies.